Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction

The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Antagonizing the overactivation of the MR with MR antagonists (MRA) is a therapeutic option, but their use in patients with CKD is limited due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima-Posada, Ixchel, Stephan, Yohan, Soulié, Matthieu, Palacios-Ramirez, Roberto, Bonnard, Benjamin, Nicol, Lionel, Kolkhof, Peter, Jaisser, Frederic, Mulder, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916671/
https://www.ncbi.nlm.nih.gov/pubmed/36768859
http://dx.doi.org/10.3390/ijms24032536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916671/
https://www.ncbi.nlm.nih.gov/pubmed/36768859
http://dx.doi.org/10.3390/ijms24032536

Ejemplares similares